Recently, Rebecca Diamond heard from friends who had gone on a GLP-1 like Ozempic or Wegovy that people treated them differently after significant weight loss . As an economics professor at Harvard, this piqued her interest. "I went to just look to see what the literature says on economic and social outcomes of these drugs," Diamond told me. "But I couldn't find a paper, which I was sort of shocked by." So she took it upon herself to dig through the data and published a new paper on her